190953-69-6

Basic information

• Product Name: CHEMBRDG-BB 4012298
• Synonyms: CHEMBRDG-BB 4012298;1-(2-PHENYLETHYL)PIPERAZIN-2-ONE;1-(2-phenylethyl)piperazin-2-one(SALTDATA: HCl);1-(2-phenylethyl)-2-Piperazinone
• CAS NO: 190953-69-6
• Molecular Formula: C₁₂H₁₆N₂O
• Molecular Weight: 204.27
• Mol File: 190953-69-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 386.097°C at 760 mmHg
• Flash Point: 187.305°C
• Appearance: /
• Density: 1.085g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.542
• CAS DataBase Reference: CHEMBRDG-BB 4012298(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMBRDG-BB 4012298(190953-69-6)
• EPA Substance Registry System: CHEMBRDG-BB 4012298(190953-69-6)

Safety Data

• Hazardous Substances Data: 190953-69-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H16N2O/c15-12-10-13-7-9-14(12)8-6-11-4-2-1-3-5-11/h1-5,13H,6-10H2

Upstream product

• 584-08-7 potassium carbonate 
• 190953-68-5 2-[(bromoacetyl)(2-phenylethyl)amino]ethyl carbamic acid tert-butyl ester 
• 156-28-5 2-phenylethylamine hydrochloride 
• 190953-67-4 2-(2-phenylethylamino)ethylcarbamic acid tert-butyl ester 

Relevant articles and documents

BICYCLIC HETEROARYL-ALKYLENE-(HOMO)PIPERAZINONES AND THIONE ANALOGUES THEREOF, THEIR PREPARATION, AND THEIR USE OF AS SELECTIVE AGONISTS OF 5HT1-LIKE RECEPTORS

A class of piperazinones, homopiperazinones and thione analogues thereof, substituted at the 1-position by an optionally substituted alkenyl, alkynyl, aryl-alkyl or heteroaryl-alkyl moiety, and linked at the 4-position via an alkylene spacer to a fused bicyclic heteroaromatic moiety, typically indolyl, are selective agonists of 5-HT. sub.1-like receptors, being potent agonists of the human 5-HT 1Dα receptor subtype while possessing at least a 10-fold selective affinity for the 5-HT 1Dα receptor subtype relative to the 5-HT 1D. beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT 1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT 1D receptor agonists.